Table 1 General baseline characteristics of participants

All participants

297

236

61

Gender

0.483

 Male

201 (67.68%)

162 (68.64%)

39 (63.93%)

 Female

96 (32.32%)

74 (31.36%)

22 (36.07%)

Age(year)

58.03 ± 13.19

58.58 ± 12.76

55.89 ± 14.64

0.203

PFA (cm²)

14.90 ± 10.24

15.72 ± 10.44

11.76 ± 8.79

0.007^*

cPFA (cm²)

15.04 ± 10.41

15.66 ± 10.51

12.59 ± 9.72

0.011^*

Weight(kg)

66.91 ± 10.75

67.84 ± 10.57

63.34 ± 10.77

0.002^*

Height(cm)

165.57 ± 8.08

165.78 ± 8.04

164.75 ± 8.25

0.399

BMI

24.33 ± 2.87

24.65 ± 2.84

23.14 ± 2.68

 < 0.001^*

Size(cm) M (Q1, Q3), cm

4.50 (2.80, 5.90)

4.38 (2.80, 5.50)

4.99 (3.00, 6.60)

0.069^#

Tumor location

0.824

 OPLK

176 (59.26%)

142 (60.17%)

34 (55.74%)

 WPLK

115 (38.72%)

89 (37.71%)

26 (42.62%)

 unclassifiable

6 (2.02%)

5 (2.12%)

1 (1.64%)

Tumor side

0.944

 Right

157 (52.86%)

125 (52.97%)

32 (52.46%)

 Left

140 (47.14%)

111 (47.03%)

29 (47.54%)

Pathological stage 1

0.010^*

 T1a

157 (52.86%)

131 (55.51%)

26 (42.62%)

 T1b

94 (31.65%)

76 (32.20%)

18 (29.51%)

 ≥ T2

46 (15.49%)

29 (12.29%)

17 (27.87%)

Pathological stage 2

0.002^*

 T1

248 (83.50%)

205 (86.86%)

43 (70.49%)

 ≥ T2

49 (16.50%)

31 (13.14%)

18 (29.51%)

Hypertension

0.856

 Yes

143 (48.15%)

113 (47.88%)

30 (49.18%)

 No

154 (51.85%)

123 (52.12%)

31 (50.82%)

Diabetes mellitus

0.088

 Yes

51 (17.17%)

45 (19.07%)

6 (9.84%)

 No

246 (82.83%)

191 (80.93%)

55 (90.16%)